

## Guard Therapeutics hosts capital markets day

**Guard Therapeutics invites current and potential investors to a capital markets day where the company will inform the audience on main development projects and clinical strategy for the investigational drug RMC-035 (ROsgard). The event will take place on September 21, 2022, 12:00 p.m. CET, at Erik Penser Bank in Stockholm and will be streamed live.**

The capital markets day will include presentations describing an overview of the scientific foundation of RMC-035, the primary drug development program in acute kidney injury following cardiac surgery and clinical strategy in kidney transplantation. Market considerations and future pricing/reimbursement opportunities will also be discussed.

The capital markets day will feature a presentation from Professor Alexander Zarbock, M.D., from the Münster University Hospital, Germany.

To register for the event online please use the following link: <http://enews.penser.se/public/event/RegistrationForm/43425B407942405D407740> (a link to the actual meeting will be sent out via email closer to September 21st)

To register for participation in person and for lunch please use the following link: <http://enews.penser.se/public/event/RegistrationForm/43425B4076494B5D467840>

### **Agenda for Guard Therapeutic's capital markets day**

***Registration and light lunch at Erik Penser Bank (Apelbergsgatan 27, Stockholm): 12:00 – 1.00 p.m. (CET).***

***The live stream will commence at 1:00 p.m. (CET)***

- *Opening statement*
- *Acute kidney injury in cardiac surgery – an intensive care physician's perspective*  
Professor Alexander Zarbock, MD, Director of Intensive Care at Münster University Hospital
- *RMC-035 – a novel first-in-class investigational drug*  
Peter Gilmour, PhD, Head of Preclinical Science, Guard Therapeutics
- *Clinical experience with RMC-035 – an overview of Phase 1 studies & detailed overview of the Phase 2 AKITA study in cardiac surgery*  
Dr Michael Reusch, Chief Medical Officer, Guard Therapeutics

***Coffee break 2:30-2:45 p.m. (CET)***

- *Clinical strategy for RMC-035 in kidney transplantation*  
Dr Michael Reusch, Chief Medical Officer, Guard Therapeutics
- *Market considerations & future pricing/reimbursement opportunities*  
Dr Tobias L. Agervald, Chief Executive Officer, Guard Therapeutics
- *Summary and closing statement*

---

***A live question and answer session will follow the summary 3:30-4:00 p.m. (CET)***

**Professor Alexander Zarbock, M.D.**, is a globally recognized expert and Key Opinion Leader (KOL) in the field of acute kidney injury. Professor Zarbock is Director of Anesthesiology, Operative Intensive Care and Pain Therapy at the University of Münster, Germany. His research interests cover a variety of aspects of intensive care and emergency medicine with a main focus on acute kidney injury, sepsis and organ protection. He is the author of over 150 scientific articles and book chapters in this field.

**For further information, please contact:**

---

**Tobias Agervald, CEO**

Telephone: +46 8 670 65 51

E-mail: [info@guardtherapeutics.com](mailto:info@guardtherapeutics.com)

**About Guard Therapeutics**

---

Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, [ca@skmg.se](mailto:ca@skmg.se).

**Attachments**

---

[Guard Therapeutics hosts capital markets day](#)